The Cost-Sharing Solution: The New NICE Ticket
This article was originally published in RPM Report
Executive Summary
J&J's Velcade and Celgene's Revlimid illustrate how pharma has adapted to the NICE UK cost-effectiveness watchdog. Now that the UK precedents exist, there will be more to come. But are they really pharma's ticket to increased access, and do they assure the value to the health care system that they claim?You may also be interested in...
What New Cancer Pathway Programs Mean For The Drug Industry
New efforts by US payors suggest oncologics no longer enjoy the same protected reimbursement status they once did, potentially pulling the rug from under biopharma's hottest development, dealmaking, and revenue generating activities. To succeed in an increasingly competitive marketplace, biopharmas must adapt their strategies with an eye to reducing payors' overall costs.
Rising Payor Influence Means Successful Drug Launches are Rarer
Growing payor influence on the uptake of high-price products is making successful drug launches far harder to achieve. Payor power varies from one Western market to the next, but all are moving in the same direction, with weakening prescriber clout and thus also less impact from detailing on launch success.
U.K. NICE Snubs Novo's Victoza, But Drug Launches Fast In The U.S.
The U.K.'s cost-effectiveness watchdog, the National Institute of Clinical Excellence, issued draft guidance on Feb. 15 recommending only limited reimbursement for Novo Nordisk's newly-launched diabetes drug Victoza (liraglutide), despite the GLP-1 analog's proven efficacy not only in lowering blood sugar, but also in promoting weight loss
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: